The extended cash runway into 2029 reduces near-term dilution risk, but investors should await clinical data in 2026 for material catalysts. The modest improvement in losses and expenses reflects cost discipline, but no efficacy data is yet available to support valuation.
Price Chart
Executive Summary
Nkarta reported financial results for Q4 and full year 2025, highlighting a cash balance of $295.1 million, which is expected to fund operations into 2029. The company advanced dose escalation in its NKX019 autoimmune therapy trial to 4 billion cells per dose and plans to present initial clinical data from Ntrust-1 and Ntrust-2 at a medical conference in 2026. Net loss was $104.1 million for the year, with R&D and G&A expenses declining slightly year-over-year.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and investments totaled $295.1 million as of December 31, 2025, sufficient to fund operations into 2029.
- Net loss was $104.1 million ($1.41 per share) for full year 2025, compared to $108.8 million ($1.60 per share) in 2024.
- R&D expenses decreased to $90.4 million in 2025 from $96.7 million in 2024.
- G&A expenses were flat at $31.6 million in 2025 vs. $31.5 million in 2024.
- Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3, and 7 (total 12 billion cells per cycle).
- Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical conference in 2026.
Financial Impact
Reduced annual net loss by $4.7 million and lowered R&D spend by $6.3 million YoY, while extending cash runway to 2029.
Risk Factors
- Clinical data from Ntrust-1 and Ntrust-2 is not expected until 2026, creating a long information vacuum.
- As a clinical-stage biotech with no approved products, Nkarta remains highly dependent on trial outcomes and future funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262553 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $2.33 $2.91 | ▼ −24.89% | ▼ −25.95% | $2.58 (−10.73%) |
May 12, 2026 20w ago | Press Release | $3.06 $2.76 | ▼ −9.80% | ▼ −9.19% | $2.58 (−15.69%) |
Apr 15, 2026 24w ago | Press Release | $2.80 $3.06 | ▲ +9.29% | ▲ +3.47% | $2.58 (−7.86%) |
Apr 6, 2026 25w ago | EFFECT | $2.36 $3.02 | ▼ −27.97% | ▼ −18.98% | $2.58 (−9.32%) |
Mar 26, 2026 27w ago | 8-K | $2.14 $2.92 | ▼ −36.45% | ▼ −25.78% | $2.58 (−20.56%) |
Mar 25, 2026 27w ago | S-3 | $2.14 $2.92 | ▼ −36.45% | ▼ −25.78% | $2.58 (−20.56%) |
Mar 25, 2026 27w ago | Press Release | $2.14 $2.92 | ▲ +36.45% | ▲ +25.78% | $2.58 (+20.56%) |
Feb 28, 2026 30w ago | Institutional Cluster | $2.70 $2.00 | ▼ −25.93% | ▼ −17.99% | $2.58 (−4.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access